31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The primary study randomized 272 participants (mean [SD] age, 75.2 [5.5] years; 145 female participants [53.3%]). 3 key findings →
Design: clinical trial Participants: 272 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Outpatient PC is associated with benefits among patients with PDRD compared with standard care alone. 5 key findings →
Participants: 584 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Mounting evidence in adults without AD indicates that females exhibit higher tau deposition than age-matched males, particularly in the setting of elevated β-amyloid (Aβ), but the evidence for sex differences in tau accumulation rates is inconclusive. 5 key findings →
Design: meta-analysis Participants: 1,376 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Of 1583 articles, data subjected from the 24 studies (including 3562 patients who experienced delirium and 6987 controls who did not) were included in a random-effects meta-analysis for pooled effect estimates and random-effects meta-regressions to identify sources of study variance. 3 key findings →
Design: systematic review Participants: 3,562 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among 193 cognitively healthy controls, 197 patients with mild cognitive impairment, and 180 patients with AD with dementia, plasma NFL correlated with CSF NFL (Spearman ρ = 0.59, P Conclusions and relevance Plasma NFL is associated with AD diagnosis and with cognitive, biochemical, and imaging hallmarks of the disease. 3 key findings →
Design: case-control study Participants: 197 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study suggests that plasma GFAP is a sensitive biomarker for detecting and tracking reactive astrogliosis and Aβ pathology even among individuals in the early stages of AD. 5 key findings →
Design: cross-sectional Participants: 300 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 490 participants, 251 were women (51.2%) and the mean (SD) age was 65.9 (13.1) years. 4 key findings →
Design: cohort study Participants: 225 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Exclusion criteria included any significant neurologic disorder other than suspected AD; presence of infection, infarction, or multiple lacunes as detected by magnetic resonance imaging; and any significant systemic condition that could lead to difficulty complying with the protocol. 3 key findings →
Design: cohort study Participants: 1,113 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Data from 17 107 individuals (321 Asian, 635 Black, 829 Hispanic, and 15 322 White) with MCI or dementia and amyloid PET were analyzed between April 2020 and January 2022. 2 key findings →
Design: cohort study Participants: 3,154 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 236 eligible participants screened, 43 were excluded. 2 key findings →
Design: longitudinal study Participants: 142 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Contrary to long-standing views, men and women with the APOE ε3/ε4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 54 adults assessed for eligibility, 11 did not meet study criteria, and 9 declined to participate. 2 key findings →
Participants: 34 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Avagacestat did not demonstrate efficacy and was associated with adverse dose-limiting effects. 5 key findings →
Design: randomized controlled trial Participants: 263 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Compared with participants who learned that they had a not elevated amyloid result, individuals who learned of an elevated amyloid result were no more likely to experience short-term increases in depression (mean [SD] change in the Geriatric Depression Scale score, 0.02 [1.3] vs 0.04 [1.3]; P = .90), anxiety (mean [SD] change in State-Trait Anxiety Inventory score, -0.02 [3.2] vs -0.15 [3.0]; P = .65), or suicidality (mean [SD] change in the Columbia Suicide Severity Rating Scale score, 0.0 [0.4] vs -0.01 [0.5]; P = .67). 5 key findings →
Design: cohort study Participants: 1,167 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Twenty-six randomized clinical trials were eligible for inclusion (N = 164 531 participants), of which 23 trials (n = 160 191 participants) reported the incidence of dementia or cognitive impairment, including 12 trials evaluating SGLT2is, 10 trials evaluating GLP-1RAs, and 1 trial evaluating pioglitazone (no trials of metformin were identified). 5 key findings →
Design: meta-analysis Participants: 164 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Midlife vascular risk factors are associated with increased risk of dementia in black and white ARIC Study participants. 4 key findings →
Design: prospective cohort Participants: 744 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment. 3 key findings →
Design: cohort study Participants: 7,540 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Baseline and 3-month visit data were available for 272 participants in arm 1 and 260 in arm 2 (median [IQR] age: 71 [65-77] and 71 [65-77] years; 150/272 male [55%] and 135/260 male [52%]; 122/272 female [45%] and 125/260 female [48%]; median [IQR] education: 12 [10-15] and 13 [10-16] years, respectively). 3 key findings →
Participants: 844 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Despite undetectable TPI-287 levels in CSF, CSF biomarkers demonstrated decreased chitinase-3-like protein-1 (YKL-40) levels in the 4RT treatment arm (mean [SD], -8.4 [26.0] ng/mL) compared with placebo (mean [SD], 10.4 [42.3] ng/mL; median difference, -14.6 [95% CI, -30.0 to 0.2] ng/mL; P = .048, Mann-Whitney test). 3 key findings →
Design: clinical trial Participants: 39 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Of 157 participants initially assessed, 137 were enrolled in the Age-Well clinical trial, and 127 were analyzed in this study. 5 key findings →
Design: cross-sectional Participants: 157 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
change from baseline in Preclinical Alzheimer Cognitive Composite score. 5 key findings →
Participants: 189 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Of 200 participants, 99 were assigned to methylphenidate and 101 to placebo. 5 key findings →
Design: longitudinal study Participants: 200 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In this study, several factors, mostly modifiable, were associated with a higher risk of YOD. 4 key findings →
Design: cohort Participants: 356,052 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A higher percentage of daily energy consumption of ultraprocessed foods was associated with cognitive decline among adults from an ethnically diverse sample. 5 key findings →
Design: cohort Participants: 10,775 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. 5 key findings →
Design: cross-sectional Participants: 2,916 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events